Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

View More View Less
  • 1 Memorial Sloan Kettering Cancer Center;
  • | 2 The University of Texas MD Anderson Cancer Center;
  • | 3 Huntsman Cancer Institute at the University of Utah;
  • | 4 University of Michigan Rogel Cancer Center;
  • | 5 Fred & Pamela Buffet Cancer Center;
  • | 6 Vanderbilt-Ingram Cancer Center;
  • | 7 Dana-Farber/Brigham and Women’s Cancer Center;
  • | 8 Mayo Clinic Cancer Center;
  • | 9 UC San Diego Moores Cancer Center;
  • | 10 UCSF Helen Diller Family Comprehensive Cancer Center;
  • | 11 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • | 12 Roswell Park Comprehensive Cancer Center;
  • | 13 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • | 14 Abramson Cancer Center at the University of Pennsylvania;
  • | 15 Stanford Cancer Institute;
  • | 16 UT Southwestern Simmons Comprehensive Cancer Center;
  • | 17 University of Wisconsin Carbone Cancer Center;
  • | 18 University of Colorado Cancer Center;
  • | 19 UC Davis Comprehensive Cancer Center;
  • | 20 City of Hope National Medical Center;
  • | 21 Kidney Cancer Coalition;
  • | 22 Yale Cancer Center/Smilow Cancer Hospital;
  • | 23 Moffitt Cancer Center;
  • | 24 Massachusetts General Hospital Cancer Center;
  • | 25 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • | 26 O'Neal Comprehensive Cancer Center at UAB;
  • | 27 Fox Chase Cancer Center;
  • | 28 Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • | 29 Duke Cancer Institute;
  • | 30 UCLA Jonsson Comprehensive Cancer Center;
  • | 31 Siteman Cancer Center at Barnes- Jewish Hospital and Washington University School of Medicine;
  • | 32 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • | 33 National Comprehensive Cancer Network.

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide management of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as “Preferred,” “Other Recommended Regimens,” or “Useful in Certain Circumstances.” This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.

Individual Disclosures for the NCCN Kidney Cancer Panel
Individual Disclosures for the NCCN Kidney Cancer Panel

  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:733.

  • 2.

    Cancer Stat Facts SEER. Kidney and Renal Pelvis Cancer. Bethesda, MD: National Cancer Institute. Accessed June 28, 2019. Available at: http://seer.cancer.gov/statfacts/html/kidrp.html.

    • Search Google Scholar
    • Export Citation
  • 3.

    Moch H, Gasser T, Amin MB, et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604614.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010;183:13091315.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Lipworth L, Morgans AK, Edwards TL, et al. Renal cell cancer histological subtype distribution differs by race and sex. BJU Int 2016;117:260265.

  • 6.

    Pathology and genetics of tumours of the urinary system and male genital organs. In: World Health Organization Classification of Tumours. Lyon, France: IARC press;2004.

    • Search Google Scholar
    • Export Citation
  • 7.

    Msaouel P, Hong AL, Mullen EA, et al. Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma. Clin Genitourin Cancer 2019;17:16.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Choyke PL, Glenn GM, Walther MM, et al. Hereditary renal cancers. Radiology 2003;226:3346.

  • 9.

    DeVita VT Jr., Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 8th Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • 10.

    Schmidt LS, Linehan WM. Genetic predisposition to kidney cancer. Semin Oncol 2016;43:566574.

  • 11.

    DeVita VT Jr., Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 10th Ed. Philadelphia, PA: Wolters Kluwer Health; 2015.

    • Search Google Scholar
    • Export Citation
  • 12.

    Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. National Cancer Institute, Bethesda, MD. 2017. Available at https://seer.cancer.gov/csr/1975_2014/

    • Search Google Scholar
    • Export Citation
  • 13.

    Ficarra V, Schips L, Guillè F, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 2005;104:968974.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Frank I, Blute ML, Leibovich BC, et al. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005;173:18891892.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol 2001;166:5458.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Klatte T, Patard JJ, Goel RH, et al. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol 2007;178:3540., discussion 40.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Lam JS, Klatte T, Patard JJ, et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 2007;52:155162.

  • 18.

    Minervini A, Lilas L, Minervini R, et al. Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer 2002;94:25902595.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Dall’Oglio MF, Antunes AA, Sarkis AS, et al. Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int 2007;100:552555.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Dall’Oglio MF, Ribeiro-Filho LA, Antunes AA, et al. Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. J Urol 2007;178:425428., discussion 428.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Lam JS, Shvarts O, Said JW, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 2005;103:25172525.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005;104:511520.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012;23:973980.

  • 24.

    Meyer CP, Sun M, Karam JA, et al. Complications after metastasectomy for renal cell carcinoma: a population-based assessment. Eur Urol 2017;72:171174.

  • 25.

    Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289296.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:57945799.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832841.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14:141148.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116:33783388.

  • 30.

    Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185:6066.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379:417427.

  • 32.

    Motzer RJ, Russo P. Cytoreductive nephrectomy - patient selection is key. N Engl J Med 2018;379:481482.

  • 33.

    Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol 2021;80:417424.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Siva S, Ellis RJ, Ponsky L, et al. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol 2016;12:637645.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Siva S, Louie AV, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer 2018;124:934942.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Meyer E, Pasquier D, Bernadou G, et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group. Eur J Cancer 2018;98:3847.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Food and Drug Administration. FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. Accessed December 6, 2021. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma

    • Search Google Scholar
    • Export Citation
  • 38.

    Pembrolizumab (KEYTRUDA) prescribing information. Accessed November 4, 2021. Available at: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf

    • Search Google Scholar
    • Export Citation
  • 39.

    Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:11161127.

  • 40.

    Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21:15631573.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma. Accessed November 4, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma

    • Search Google Scholar
    • Export Citation
  • 42.

    Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384:829841.

  • 43.

    FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma. Accessed November 4, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvatinib-plus-pembrolizumab-advanced-renal-cell-carcinoma

    • Search Google Scholar
    • Export Citation
  • 44.

    Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:12891300.

  • 45.

    FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. Accessed November 4, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-combination-intermediate-or-poor-risk-advanced-renal-cell

    • Search Google Scholar
    • Export Citation
  • 46.

    Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:12771290.

  • 47.

    Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial. J Clin Oncol 2017;35:591597.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48.

    Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:11031115.

  • 49.

    Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020;31:10301039.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:10611068.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 51.

    Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49:12871296.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52.

    Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722731.

  • 53.

    Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;370:17691770.

  • 54.

    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115124.

  • 55.

    Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:1624.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884896.

  • 57.

    Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:2535.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:35843590.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 2016;17:13171324.

  • 60.

    Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:19311939.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14:12871294.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133141.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Rosenberg SA, Mulé JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:11691188.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:31273132.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:22712281.

  • 66.

    Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:18141823.

  • 67.

    Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917927.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Motzer RJ, Escudier B, Powles T, et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 2018;118:11761178.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Amzal B, Fu S, Meng J, et al. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLoS One 2017;12:e0184423.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Lenvatinib (LENVIMA) prescribing information. Accessed November 4, 2021. Available at: http://www.lenvima.com/pdfs/prescribing-information.pdf

  • 71.

    FDA approves lenvatinib in combination with everolimus for advanced renal cell carcinoma. Accessed November 4, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/lenvatinib-combination-everolimus

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16:14731482.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Motzer RJ, Hutson TE, Ren M, et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17:e4e5.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:18031813.

  • 75.

    Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol 2017;72:962971.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552562.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Apolo AB, Nadal R, Girardi DM, et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. J Clin Oncol 2020;38:36723684.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 78.

    Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors. ASCO; 2021. Accessed November 4, 2021. Available at: https://meetinglibrary.asco.org/record/194730/abstract

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 2017;35:38513858.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Lee CH, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 2021;22:946958.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Hainsworth JD, Rubin MS, Arrowsmith ER, et al. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clin Genitourin Cancer 2013;11:270275.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:25162524.

  • 83.

    Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:6167.

  • 84.

    Eichelberg C, Heuer R, Chun FK, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54:13731378.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182:2934., discussion 34.

  • 86.

    Zimmermann K, Schmittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76:350354.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Garcia JA, Hutson TE, Elson P, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010;116:53835390.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 88.

    FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma. Accessed November 4, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma

    • Search Google Scholar
    • Export Citation
  • 89.

    Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol 2020;21:95104.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449456.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:42564265.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427434.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:18551861.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:54725480.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:16881694.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965972.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:70997109.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125134.

  • 99.

    Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:33123318.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:760767.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    de Velasco G, McKay RR, Lin X, et al. Comprehensive analysis of survival outcomes in non-clear cell renal cell carcinoma patients treated in clinical trials. Clin Genitourin Cancer 2017;15:652660.e1.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Pal SK, Tangen C, Thompson IM, Jr., et al.A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 2021;397:695703.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 2016;17:378388.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 2016;69:866874.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Ciccarese C, Iacovelli R, Brunelli M, et al. Addressing the best treatment for non-clear cell renal cell carcinoma: a meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. Eur J Cancer 2017;83:237246.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Hutson TE, Michaelson MD, Kuzel TM, et al. A single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2021;80:162170.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Koshkin VS, Barata PC, Zhang T, et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer 2018;6:9.

  • 108.

    McKay RR, Bossé D, Xie W, et al. The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. Cancer Immunol Res 2018;6:758765.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    McDermott DF, Lee JL, Ziobro M, et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol 2021;39:10291039.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Park I, Lee SH, Lee JL. A multicenter phase II trial of axitinib in patients with recurrent or metastatic non-clear-cell renal cell carcinoma who had failed prior treatment with temsirolimus. Clin Genitourin Cancer 2018;16:e997e1002.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Irshad T, Olencki T, Zynger DL, et al. Bevacizumab in metastatic papillary renal cell carcinoma (PRCC) [abstract]. J Clin Oncol 2011;29:e15158.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 112.

    Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer 2014;13:637644.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Srinivasan R, Gurram S, Al Harthy M, et al. Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. J Clin Oncol 2020;38(15_suppl):50045004.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 114.

    Voss MH, Molina AM, Chen YB, et al. Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J Clin Oncol 2016;34:38463853.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Buti S, Bersanelli M, Maines F, et al. First-line pazopanib in non-clear-cell renal carcinoma: the Italian retrospective multicenter PANORAMA study. Clin Genitourin Cancer 2017;15:e609e614.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27:57885793.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Blank CU, Bono P, Larkin JMG, et al. Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: subgroup analysis of REACT [abstract]. J Clin Oncol 2012; 30(5, suppl)402. (Abstract 402)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 118.

    Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013;24:10261031.

  • 119.

    Escudier B, Molinie V, Bracarda S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer 2016;69:226235.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Jung KS, Lee SJ, Park SH, et al. Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study. Cancer Res Treat 2018;50:488494.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Costello BA, Ho TH, Burbano GP, et al. A phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell cancer (mRCC) PINCR [abstract]. J Clin Oncol 2020;38 (Suppl):696696.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 122.

    Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202209.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Venugopal B, Ansari J, Aitchison M, et al. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urol 2013;13:26.

  • 124.

    Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: the Bronx experience. Urology 2007;70:878882.

  • 125.

    Watanabe IC, Billis A, Guimarães MS, et al. Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol 2007;20:914920.

  • 126.

    Shah AY, Karam JA, Malouf GG, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int 2017;120:782792.

  • 127.

    Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol 2009; 22(S2, Suppl 2)S2S23.

  • 128.

    Tokuda N, Naito S, Matsuzaki O, et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 2006;176:4043., discussion 43.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Karakiewicz PI, Trinh QD, Rioux-Leclercq N, et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol 2007;52:11401145.

  • 130.

    Gupta R, Billis A, Shah RB, et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol 2012;36:12651278.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol 2007;177:16981702.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Roubaud G, Gross-Goupil M, Wallerand H, et al. Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. Oncology 2011;80:214218.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 133.

    Fokas E, Henzel M, Hamm K, et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery? Analysis of 88 patients. Strahlenther Onkol 2010;186:210217.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Zekri J, Ahmed N, Coleman RE, et al. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001;19:379382.

  • 135.

    Schlesinger-Raab A, Treiber U, Zaak D, et al. Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. Eur J Cancer 2008;44:24852495.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Roza T, Hakim L, van Poppel H, et al. Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions. Drugs Aging 2013;30:877886.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Hunter GK, Balagamwala EH, Koyfman SA, et al. The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Pract Radiat Oncol 2012;2:e95e100.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2012;82:17441748.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962969.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:26132621.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:11251132.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1170 1170 1170
PDF Downloads 654 654 654
EPUB Downloads 0 0 0